U.S. Office — Brooklyn, NY · Mon–Fri 9:00–18:00 ET
Direct: +1 (347) 567-0781 · Email: info@sucotondusa.com
ProductsAboutCertificationsVerify FactoryBlogContact
Custom Development · Private Label

Define the species, material basis and extract before calling it a mushroom blend.

Sucotond USA coordinates non-confidential feasibility review for U.S. brands planning functional, non-psychoactive mushroom gummies. The review connects taxonomic identity, organism part or culture basis, material form, label amount, marker method, gummy matrix, package and evidence before a commercial commitment.

This is a custom-project service page, not a claim that one stocked species, blend, extract, dose, method, formula or shelf life fits every project.

Finished functional gummy bottles on the production lineProject Starting Point
Taxonomic identitySpecies and material reviewed
Material basisPart, culture, powder or extract defined
Label amountServing and ingredient basis reconciled
Marker and methodAnalyte- and matrix-specific
Package and stabilityConnected to the finished formula
MOQ and timingConfirmed after feasibility
Current service status: open for functional, non-psychoactive mushroom concepts only. This page does not identify an approved Sucotond species, blend or formula. A sample, quote or production path begins only after the material, intended use, safety and label basis, gummy system, testing, package and commercial scope are reviewed.
Keep Four Concepts Separate

“Mushroom extract” is not a complete ingredient specification

A reviewable brief identifies what organism is intended, what material was produced, how it was processed and which measured attribute belongs on the specification or label.

Species identity

Common names can be ambiguous. Capture a reviewable scientific name, supplier naming, reference material and the identity evidence applicable to the received ingredient.

Organism part or culture basis

Fruiting body, mycelium and fermentation biomass are not interchangeable descriptions. Record substrate or culture context and harvest basis where relevant to the material.

Powder, extract and carrier

Whole powder, concentrated extract, dried extract and formulated ingredient can carry different extraction ratios, solvents, carriers, excipients and compositional specifications.

Measured attribute

Total polysaccharides, alpha-glucans, beta-glucans and other markers are different terms. Define the analyte, method, sample preparation, units and acceptance decision.

Category boundary: this service excludes Amanita muscaria, muscimol, ibotenic acid, psilocybin, psilocin, psychedelic, microdose and “legal high” edible projects or claims. It also makes no cognitive, immune, energy, stress, gut, disease or other finished-product health claim. The responsible brand must obtain qualified U.S. ingredient-status, safety, labeling and claims review for the exact product.
Before a Quote

Eight decisions that make a mushroom gummy project reviewable

1. Species and naming

  • Scientific and common name for each intended species
  • Single-species or defined multi-species concept
  • Supplier identity and reference documentation
  • How the name will appear in formula, specification and label

2. Material and process basis

  • Fruiting body, mycelium or other reviewed basis
  • Powder, extract or formulated ingredient
  • Cultivation/fermentation, extraction and concentration context
  • Carrier, substrate-derived material and other excipients

3. Serving and label basis

  • Amount per serving and acceptable piece count
  • Individual amounts or a defined blend
  • Source/material wording and ingredient-list reconciliation
  • Claims and label approval responsibility

4. Attribute and analytical method

  • Identity, composition or marker decision being made
  • Beta-glucan versus total-polysaccharide terminology
  • Method, sample preparation, units and matrix suitability
  • Laboratory scope and result limitations

5. Safety and regulatory path

  • Intended ingredient, use level, market and population
  • History-of-use, NDI or other review question and owner
  • Allergen, interaction or warning review inputs
  • Explicit exclusion of psychoactive/“legal high” ingredients

6. Gummy feasibility

  • Target load, piece weight and serving count
  • Flavor, color, odor, texture and sediment questions
  • Gelling, sweetener, acid and coating system
  • Sample-to-commercial differences and change triggers

7. Quality and contaminant plan

  • Component and finished-product specifications
  • Identity, composition and relevant contaminant criteria
  • Supplier qualification, sampling and test responsibilities
  • Batch records, deviations and quality disposition

8. Package, stability and commercial scope

  • Container, closure, count, storage and distribution route
  • Formula/package/time-point evidence expectations
  • Market, volume stage, delivery point and records
  • MOQ, timing and quote validity confirmed after review
Specification Map

Make every mushroom field carry its own evidence question

The table is intentionally not prefilled with a species, extract ratio, dose, beta-glucan value or shelf life. Those values become publishable only when they belong to the approved project and evidence scope.

Project fieldBuyer inputRequired confirmation before commitment
Taxonomic identityEach intended scientific/common name or acceptance criteriaSupplier naming, identity specification, method/reference and lot connection
Material basisFruiting body, mycelium, biomass or other reviewed sourceCultivation/fermentation, substrate, harvest and source-material description as applicable
Processing basisPowder, extract, concentration direction and exclusionsExtraction, solvent, ratio or native-equivalent basis, carrier and excipient reconciliation
Serving and labelAmount, serving, blend disclosure and proposed wordingFormula basis, units, ingredient list, market review and effective artwork
Attribute and methodIdentity/composition/marker claim and evidence expectedAnalyte definition, method, preparation, matrix suitability, units and acceptance criteria
Gummy systemLoad, piece count, gelling/sweetener system and sensory directionApproved formula, manufacturability, sample transfer, process controls and change triggers
Package and shelf lifeContainer, closure, count, storage wording and proposed dateCommercial formula/package, conditions, time points, results, trend and quality decision
Commercial termsMarket, volume stage, delivery point and launch windowMaterials, package, evidence scope, quantity, timing and current quote
Evidence Chain

Connect the named species to the released commercial lot

Supplier material

Species, source basis, process, lot, carrier and component criteria.

Incoming decision

Identity evidence, sampling, acceptance and supplier qualification.

Approved formula

Serving, gummy system, label basis, package and controlled revision.

Commercial process

Master/batch records, controls, yields, sampling and deviations.

Finished evidence

Applicable identity, composition, contaminants and disposition.

Time and label

Package, storage, time points, effective artwork and distributed lot.

Use the product specification checklist to define acceptance fields, the laboratory report checklist to review analyte and method scope, the shelf-life evidence checklist to connect the package and time points, and the label/artwork checklist to control the final wording.

Government Category Context

Functional mushroom and psychoactive edible concepts are not one project category

Define the non-psychoactive ingredient

Operation Supplement Safety, a U.S. Department of Defense program, describes common functional-mushroom label terms and distinguishes fruiting body and mycelium materials. It also warns that products marketed as a “legal high” are a separate, riskier category. That supports an exact ingredient brief; it does not establish efficacy or approve a Sucotond material.

Operation Supplement Safety: Mushroom Dietary Supplements

Why Amanita is outside this service

FDA's December 2024 alert states that Amanita muscaria, its extracts and certain constituents are not authorized for use as ingredients in conventional food. FDA's separate 2024 Diamond Shruumz investigation concerned specific recalled products. Those records justify a clear exclusion; they do not imply that ordinary functional-mushroom supplements share the recalled formulation or cause.

FDA Amanita industry and consumer alert

Identity Evidence

One identity method can answer one question without proving the whole material

A peer-reviewed study evaluated DNA barcoding for consumer-relevant mushroom materials and described it as useful in many tested samples, including some processed materials. The authors framed it as a partial identity tool—not a universal answer. Extraction, degradation, mixed-species products, reference coverage and sample context can affect what an identity approach can resolve. A project must match the method to the received material and decision.

PubMed: DNA barcoding for consumer-relevant mushrooms

Beta-Glucan Method Context

The gummy matrix belongs in the method review

A 2026 Journal of AOAC INTERNATIONAL research paper examined indirect enzymatic beta-glucan workflows across mushrooms, yeast, algae and supplements. It reported matrix-dependent issues involving resistant starches, trehalose and maltitol and evaluated workflow refinements. This is useful method-development context, but it does not establish a Sucotond result, approve one method for every gummy or make beta-glucan interchangeable with total polysaccharides.

PubMed: Advances in enzymatic beta-glucan measurement

CGMP and Claims Connection

Identity, composition and marketing evidence remain separate decisions

FDA's dietary-supplement CGMP guide describes component identity and specifications, appropriate scientifically valid tests or examinations, finished-product specifications, packaging and label specifications, master/batch records and quality-control disposition. FDA's claims-substantiation guidance separately explains why ingredient, dose, formulation, population and study design matter when evaluating claim evidence.

  • Identity: determine whether the received material is what the component specification says it is.
  • Composition: define which amount or marker is measured, by what method and against which criterion.
  • Contaminants: establish relevant limits and test/examination responsibilities for the actual material and product.
  • Finished product: connect the approved formula, batch, package, test results and quality disposition.
  • Claims: do not transfer evidence from another species, extract, dose, formula or population to an unreviewed gummy.

FDA Dietary Supplement CGMP Small Entity Compliance Guide · FDA dietary-supplement claims substantiation guidance

Responsibility Map

Keep sales, manufacturing, brand and evidence roles visible

Brooklyn project office

Sucotond USA coordinates non-confidential buyer inputs, commercial communication, evidence requests, project status and delivery planning. It does not select a species or approve a health claim for the brand.

Guangzhou production facility

The company identifies Sucotond (Guangzhou) Health Biotechnology Co., Ltd. as responsible for development, feasibility, production, in-process controls and batch records. Facility evidence and product evidence remain separate.

Brand / responsible firm

The brand defines the intended market, material and claim basis, approves the formula/specification and obtains qualified safety, NDI, labeling and substantiation review for the exact product.

Ingredient supplier and laboratory

Supplier and laboratory records must match the exact material lot, sample, analyte, method and report. A COA or identity result does not automatically authorize public use or validate another batch.

Buyer FAQ

Functional mushroom gummy project questions

What mushroom information is needed before requesting a gummy quote?

Identify each intended species using a reviewable scientific and common name, the organism part or culture basis, whether the material is a powder or extract, the supplier form and carrier, the amount and serving basis, proposed marker or attribute, target market, package and evidence requirements. If the ingredient is not selected, state the acceptance criteria rather than inventing a blend.

Are fruiting body, mycelium, biomass, powder and extract interchangeable?

No. They describe different material or processing bases. Preserve the supplier identity, source material, cultivation or fermentation context where relevant, extraction and concentration basis, carrier or excipients and applicable specifications through formula and label review.

Does a polysaccharide value prove a beta-glucan amount?

Not by itself. State the analyte definition, method, sample preparation, units, matrix suitability and acceptance criteria. Current research also shows that some gummy-relevant carbohydrates and sweeteners can affect indirect enzymatic workflows, so the laboratory and project team should evaluate the actual matrix.

Does Sucotond USA work on psychoactive mushroom edibles?

No. This service page is limited to functional, non-psychoactive mushroom dietary-supplement concepts and excludes the ingredients, substances and marketing categories listed in the boundary above.

What evidence can a brand request for a commercial mushroom gummy project?

Define supplier and lot identity records, component specifications and applicable safety review, approved formula and product specification, sample approval, master and batch records, agreed identity, composition and contaminant reports, packaging and label revision, stability evidence and quality disposition. Availability and disclosure rights depend on the project and document owners.

Non-Confidential Project Intake

Request a functional mushroom gummy feasibility map

Share the intended species/material status, serving, gummy system, package, market, volume stage, evidence expectations and timing. The review identifies open questions; it is not a formula, quote, method, result or production commitment.

U.S. Office
7624 17th Ave
Brooklyn, NY 11214
Business Hours
Monday–Friday, 9:00–18:00 ET

Do not submit confidential formula details before an NDA is in place. By submitting, you agree that Sucotond USA may use these details to evaluate and respond to the inquiry. Privacy notice.

Thanks — your brief was received.
The project inputs are ready for internal review.
WhatsApp+1 (347) 495-0089 Email Usinfo@sucotondusa.com